Firefly Neuroscience, Inc.
AIFF
$2.24
$0.2613.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 957.41% | 958.11% | 568.75% | -72.48% | -78.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 957.41% | 958.11% | 568.75% | -72.48% | -78.31% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 497.22% | 597.30% | 529.69% | -72.48% | -78.31% |
| SG&A Expenses | 4.55% | 14.97% | 149.97% | 158.34% | 158.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.87% | 14.40% | 135.67% | 149.35% | 159.73% |
| Operating Income | 7.35% | -5.86% | -129.60% | -180.26% | -198.25% |
| Income Before Tax | -90.07% | -173.27% | -455.23% | -602.18% | -302.85% |
| Income Tax Expenses | 150.00% | 500.00% | 500.00% | 100.00% | 100.00% |
| Earnings from Continuing Operations | -90.08% | -173.31% | -455.24% | -602.02% | -302.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.08% | -173.31% | -455.24% | -602.02% | -302.77% |
| EBIT | 7.35% | -5.86% | -129.60% | -180.26% | -198.25% |
| EBITDA | -4.15% | -21.42% | -201.73% | -301.55% | -163.67% |
| EPS Basic | -52.11% | -85.40% | -215.25% | -335.75% | -194.97% |
| Normalized Basic EPS | -28.23% | -43.95% | -156.32% | -257.67% | -175.38% |
| EPS Diluted | -52.11% | -85.40% | -215.25% | -335.75% | -194.97% |
| Normalized Diluted EPS | -28.23% | -43.95% | -156.32% | -257.67% | -175.38% |
| Average Basic Shares Outstanding | 90.02% | 111.91% | 116.37% | -35.33% | -56.91% |
| Average Diluted Shares Outstanding | 90.02% | 111.91% | 116.37% | -35.33% | -56.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |